All In Biotech

Drug Trial Radar · NCT07570654

Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Sep 14, 2026

Primary completion

Nov 2028

Study completion Sep 2029

Sponsor

Lead sponsor
COMPASS PathwaysIndustry
Sponsor type
Industry
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.

Conditions

  • PTSD - Post Traumatic Stress Disorder
  • PTSD
  • PTSD Symptoms
  • PTSD, Post Traumatic Stress Disorder

Interventions

  • COMP360 psilocybinDrug

    COMP360 psilocybin administered with monitoring and support

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. COMP360 25 mg versus COMP360 1 mg change from Baseline to Week 8 in CAPS-5 total severity scoreTime frame: 8 weeks

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • AZ

    Tucson, Arizona · Recruiting

  • CA

    Irvine, California · Recruiting

  • CA

    Los Angeles, California · Recruiting

  • CA

    Moorpark, California · Recruiting

  • CA

    San Jose, California · Recruiting

  • FL

    Miami, Florida · Recruiting

  • FL

    Orlando, Florida · Recruiting

  • IL

    Chicago, Illinois · Recruiting

  • MA

    Boston, Massachusetts · Recruiting

  • MN

    Eden Prairie, Minnesota · Recruiting

  • NE

    Lincoln, Nebraska · Recruiting

  • NV

    Las Vegas, Nevada · Recruiting

  • NY

    New York, New York · Recruiting

  • NY

    The Bronx, New York · Recruiting

  • OH

    North Canton, Ohio · Recruiting

  • TX

    Carrollton, Texas · Recruiting

  • UT

    Orem, Utah · Recruiting

  • BC

    Kamloops, British Columbia, Canada · Recruiting

  • BC

    North Vancouver, British Columbia, Canada · Recruiting

  • BC

    Penticton, British Columbia, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.